# Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

> **NCT00258778** · PHASE1 · COMPLETED · sponsor: **Protalix** · enrollment: 6 (—)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Human Glucocerebrosidase (prGCD)

## Key facts

- **NCT ID:** NCT00258778
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 6 (—)
- **Last updated:** 2006-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258778, "Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT00258778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*